Magnolol Encapsulated by Liposome in Inhibiting Smooth Muscle Cell Proliferation

Chen, Calvin Yu-Chian; Wu, Chieh Hsi

doi:10.1002/jccs.200800076

Cited by 9 publications

(6 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pure Uio-66(Zr) and mag@Uio-66(Zr) were characterized and compared to assess magnolol impregnation by thermogravimetric analysis (TGA), powder X-ray diffraction (PXRD), and nitrogen sorption isothermal techniques. Our study reports Approaches to increase the bioavailability of magnolol include the use of micellar particles [12,13], mesoporous silica [14], nanoparticles [15,16], solid dispersions [17,18], and liposomes [19]. As part of our continuing efforts to increase the bioavailability of biologically active natural products with limited solubility in aqueous systems, a metal organic framework (MOF) was utilized in this study as drug delivery system for crystalline yellow magnolol (1).…”

Section: Introductionmentioning

confidence: 99%

Enhanced Oral Bioavailability of the Pharmacologically Active Lignin Magnolol via Zr-Based Metal Organic Framework Impregnation

et al. 2020

View full text Add to dashboard Cite

Bioavailability plays an important role in drug activity in the human body, as certain drug amounts should be present to elicit activity. However, low bioavailability of drugs leads to negligible use for human benefit. In this study, the diversely active neolignan, magnolol, was impregnated onto a Zr-based organometallic framework [Uio-66(Zr)] to increase its low bioavailability (4–5%) and to test its potential acute oral toxicity. Synthesis of Uio-66(Zr) was done through the solvothermal method while simple impregnation at different time points was used to incorporate magnolol. The loading capacity of Uio-66(Zr) at 36 h was found to be significantly higher at 72.16 ± 2.15% magnolol than in other incubation time. Based on the OECD 425 (limit test), toxicity was not observed at 2000 mg kg−1 dose of mag@Uio-66(Zr) in female Sprague Dawley rats. The area under the curve (AUC) at 0–720 min of mag@Uio-66(Zr) was significantly higher than the AUC of free magnolol. Moreover, relative bioavailability increased almost two-folds using Uio-66(Zr). Unconjugated magnolol was found in the liver, kidney, and brain of rats in all treatment groups. Collectively, Uio-66(Zr) provided a higher magnolol bioavailability when used as drug carrier. Thus, utilization of Uio-66(Zr) as drug carrier is of importance for maximal use for poorly soluble and lowly bioavailable drugs.

show abstract

Section: Introductionmentioning

confidence: 99%

Enhanced Oral Bioavailability of the Pharmacologically Active Lignin Magnolol via Zr-Based Metal Organic Framework Impregnation

et al. 2020

View full text Add to dashboard Cite

show abstract

“…27 With these therapeutic inadequacies, many efforts have been made to design new drug carrier systems that are able to improve the drug's solubility and stability in vivo, while retaining its therapeutic efficacy. To increase its solubility and bioavailability, attempts have been made through encapsulation using liposomes 28 and cyclodextrin. 27 Traditional liposomal drug carriers are limited by low drug encapsulation efficiency, poor storage stability, rapid clearance from the bloodstream, nonspecific uptake by the mononuclear phagocytic system, poor control over release of the drug from the liposome and rapid drug loss profiles in vivo.…”

Section: ' Introductionmentioning

confidence: 99%

Magnolol-Loaded Core–Shell Hydrogel Nanoparticles: Drug Release, Intracellular Uptake, and Controlled Cytotoxicity for the Inhibition of Migration of Vascular Smooth Muscle Cells

Wang

Chien²,

et al. 2011

Mol. Pharmaceutics

Self Cite

View full text Add to dashboard Cite

Encapsulation and release behavior of a water-insoluble drug, magnolol, using a core-shell polysaccharide-based nanoparticle, manipulating the cellular internalization and controlled cytotoxic effect of magnolol-loaded nanoparticles over the A10 vascular smooth muscle cells (VSMCs) was reported. A magnolol-polyvinylpyrrolidone (PVP) core phase was prepared, followed encapsulating by an amphiphilic carboxymethyl-hexanoyl chitosan (CHC) shell to form a magnolol-loaded core-shell hydrogel nanoparticles (termed magnolol-CHC nanoparticles). The resulting magnolol-CHC nanoparticles were employed for evaluation of drug release and controlled cytotoxic inhibition of VSMCs migration in vitro. A sustained release of the magnolol from the nanoparticles was determined. The magnolol-CHC nanoparticles exhibited outstanding cellular uptake efficiency, and under a cytotoxic evaluation, an increased antiproliferative effect and effective inhibition of VSMC migration as a result of efficient intracellular delivery of the encapsulated magnolol in comparison to free magnolol was achieved. We then envision a potential intracellular medication strategy with improved biological and therapeutic efficacy using the magnolol-CHC nanoparticles illustrated in this work.

show abstract

“…Also, magnolol-EPC was more effective than DPPC liposome. 168 HUVECs were used to investigate the antiinflammatory mechanisms of magnolol NPs. In vitro administration of magnolol NPs was shown to suppress the activity of TNFα-induced VCAM-1 promoter.…”

Section: Resveratrolmentioning

confidence: 99%

“…Also, magnolol-EPC was more effective than DPPC liposome. 168 …”

Section: Natural Product-based Nanoformulations For Cardiovascular Diseasesmentioning

confidence: 99%

Current Advances in the Use of Nanophytomedicine Therapies for Human Cardiovascular Diseases

Hesari¹,

Mohammadi²,

Khademi³

et al. 2021

IJN

View full text Add to dashboard Cite

Considering the high prevalence of cardiovascular diseases (CVDs), the primary cause of death during the last several decades, it is necessary to develop proper strategies for the prevention and treatment of CVDs. Given the excessive side effects of current therapies, alternative therapeutic approaches like medicinal plants and natural products are preferred. Lower toxicity, chemical diversity, cost-effectiveness, and proven therapeutic potentials make natural products superior compared to other products. Nanoformulation methods improve the solubility, bioavailability, circulation time, surface area-to-volume ratio, systemic adverse side effects, and drug delivery efficiency of these medications. This study intended to review the functionality of the most recent nanoformulated medicinal plants and/ or natural products against various cardiovascular conditions such as hypertension, atherosclerosis, thrombosis, and myocardial infarction. Literature review revealed that curcumin, quercetin, and resveratrol were the most applied natural products, respectively. Combination therapy, conjugation, or fabrication of nanoparticles and nanocarriers improved the applications and therapeutic efficacy of herbal-or natural-based nanoformulations. In the context of CVDs prevention and/or treatment, available data suggest that natural-based nanoformulations are considerably efficient, alone or in blend with other herbal/synthetic medicines. However, clinical trials are mandatory to elucidate the safety, cardioprotective effect, and mechanism of actions of nanophytomedicines.

show abstract

Magnolol Encapsulated by Liposome in Inhibiting Smooth Muscle Cell Proliferation

Cited by 9 publications

References 32 publications

Enhanced Oral Bioavailability of the Pharmacologically Active Lignin Magnolol via Zr-Based Metal Organic Framework Impregnation

Enhanced Oral Bioavailability of the Pharmacologically Active Lignin Magnolol via Zr-Based Metal Organic Framework Impregnation

Magnolol-Loaded Core–Shell Hydrogel Nanoparticles: Drug Release, Intracellular Uptake, and Controlled Cytotoxicity for the Inhibition of Migration of Vascular Smooth Muscle Cells

Current Advances in the Use of Nanophytomedicine Therapies for Human Cardiovascular Diseases

Contact Info

Product

Resources

About